leadf
logo-loader
viewUrigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals advancing its drug to to end of Phase 2 trials to treat bladder pain

Urigen Pharmaceuticals, Inc CEO Dan Vickery sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The privately-held company specializes in non-oncological urology treatments.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ascendant Resources drill program continues looking to expand south zone at...

Ascendant Resources (TSE: AND) President and CEO Chris Buncic joined Steve Darling from Proactive with news the company's drill program continues as the look at the South Zone of the Lagoa Salgada Project in Portugal. Buncic telling Proactive they are expecting to have results from this...

12 hours, 36 minutes ago

2 min read